On the Radar: Five high-value biotech stocks

Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value

The Greek company “ANTAEA Medical Services Ltd.” won the lawsuit against “ATLAS Medical Services Ltd.” and Özdemir Hiçdurmaz

The Greek company "ANTAEA Medical Services Ltd." won the lawsuit against "ATLAS Medical Services Ltd." and Özdemir Hiçdurmaz for unfair competition, in the Turkish...

Novo working up a weekly insulin; Zafgen embarks on a rare disease trial;

@FierceBiotech: Hemispherx to test FDA-rejected drug, other candidates against Ebola. FierceBiotech Research story | Follow @FierceBiotech @JohnCFierce: Baxter inks a big lease in the heart of...

Zafgen Announces Initiation of Phase 3 Trial of Beloranib in Prader-Willi Syndrome

BOSTON, Oct. 1, 2014 -- Zafgen, Inc. (ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic...

Allergan blueprints a big Texas expansion amid battle with spendthrift Valeant

Allergan has signed a lease for big chunk of office space in Texas, according to the Austin Business Journal, keeping quiet on its plans as it slashes jobs around the globe.

Biotech backer LSP banks $100M to fund a new generation of startups

European venture outfit LSP (Life Sciences Partners) has raised $100 million toward a new biotech fund, setting out to stake a dozen or so innovators in drugs, devices and diagnostics.

LSP RAISES EUR 80 MLN TO INVEST IN MEDICAL INNOVATIONS

LSP (Life Sciences Partners) today announced that it has raised EUR 80 mln (USD 100 mln) for its new fund LSP 5. This fund will continue LSP's proven and successful strategy of investing in...

Sanofi sets up a major R&D hub in booming Shanghai

French pharma giant Sanofi has unveiled plans to bring together the drug development work being done in a dozen different Pacific Rim countries, creating a major new R&D center in Shanghai that will employ 1,400 staffers.

Portola's 'breakthrough' anti-anticoagulant clears a Phase III hurdle

Portola Pharmaceuticals' antidote to Big Pharma's latest crop of blockbuster blood thinners hit the mark in its first Phase III trial, clearing the way for an FDA submission next year.

Portola Pharmaceuticals Announces Phase 3 ANNEXA(TM)-A Study of Andexanet Alfa and Eliquis (Apixaban) Met Primary and Secondary Endpoints With High Statistical Significance

Detailed Data Showing Andexanet Alfa Significantly Reversed Anticoagulation Activity of Factor Xa Inhibitor Eliquis to be Featured at American Heart Association's "Clinical Science: Special...